Regulatoriskt pressmeddelande

NET ASSET VALUE – 31 March 2026

On the 31 March 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,670 million and NAV per share was SEK 41.90. Return on NAV per share in the month was -1.09%.

Allocation of NAV	Share of portfolio company	Fair value (MSEK)	Part of NAV per share (SEK)	Share of NAV
Product Development
Lipum	100%	348	3.97	9.5%
Prokarium	50%	281	3.21	7.7%
Xspray Pharma	18%	225	2.57	6.1%
Empros Pharma	79%	204	2.33	5.6%
KAHR Medical	34%	204	2.33	5.6%
Atrogi	44%	197	2.25	5.4%
Bonsai Biotherapeutics	100%	158	1.80	4.3%
Xintela	60%	128	1.46	3.5%
Microbiotica	10%	126	1.44	3.4%
AnaCardio	13%	79	0.91	2.2%
Geneos Therapeutics	12%	68	0.78	1.9%
Mendus	23%	62	0.70	1.7%
EpiEndo Pharmaceuticals	9%	54	0.62	1.5%
Vitara Biomedical	11%	54	0.61	1.5%
Buzzard Pharmaceuticals	14%	32	0.36	0.9%
Egetis Therapeutics	1%	27	0.31	0.7%
Amarna Therapeutics	58%	11	0.13	0.3%
Strike Pharma	18%	11	0.12	0.3%
Alder Therapeutics	30%	0	0.00	0.0%
Total		2,269	25.90	61.8%

Commercial Growth
Symcel	30%	204	2.33	5.6%
NorthX Biologics	61%	202	2.30	5.5%
Chromafora	28%	137	1.57	3.7%
Nanologica	50%	59	0.68	1.6%
Frontier Biosolutions	2%	26	0.30	0.7%
Bohus Biotech	45%	0	0.00	0.0%
Total		630	7.19	17.2%

Assets related to Portfolio companies		183	2.08	5.0%
Other assets and liabilities		589	6.73	16.1%

Net Asset Value		3,670	41.90	100.0%

Flerie in brief
Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie’s active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB’s ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com